How Trauma Rewires the Brain: Neuroplasticity's Role in PTSD Development and Recovery

PTSD affects 1–8% of the global population across a lifetime, yet only 25–35% of trauma-exposed adults develop the disorder, suggesting individual neurobiological vulnerability is critical. This 2025 narrative review by López-López and Crespo examines the latest preclinical and clinical data linking neuroplasticity — at both the synaptic and myelin levels — to PTSD pathophysiology, prevention, and treatment.

At the synaptic level, traumatic experiences dysregulate the amygdala-hippocampus-prefrontal cortex (PFC) circuit, which governs fear acquisition, consolidation, and extinction. People with PTSD show synaptic loss in the dorsolateral PFC, impairing cognitive regulation. Electrophysiological interventions — transcranial magnetic stimulation (n=28) and transcranial direct current stimulation (n=130, blinded) targeting the ventromedial PFC — improved conditioned fear extinction recall, pointing to plasticity-based therapeutic windows.

BDNF (brain-derived neurotrophic factor) is central to these changes. It maintains synaptic plasticity and neurogenesis, modulates NMDA and AMPA glutamate receptors, and regulates CRH expression — linking stress-axis hormones directly to neural plasticity. The Val66Met polymorphism is especially important: the Met allele reduces BDNF transcription efficiency, transport, and secretion, leading to hippocampal and amygdalar atrophy, impaired long-term potentiation, and deficient fear extinction. Val/Val genotype appears protective while Val/Met or Met/Met increases PTSD risk. D-cycloserine, a partial NMDA agonist, has shown significant symptom improvement in some trials, though results are mixed.

Beyond synaptic plasticity, the review highlights myelinic plasticity — often overlooked — as equally important. Oligodendrocytes express glucocorticoid receptors, directly linking stress hormones to myelination. In war veterans, MRI-estimated myelination in the hippocampus correlated positively with PTSD severity (CAPS scores) and depressive symptoms. In rodents, oligodendrocyte density and myelin basic protein in the hippocampal dentate gyrus correlated with anxiety and avoidance phenotypes. Promyelinating drugs (e.g., clemastine fumarate in mice) improved remote fear memory, suggesting myelin remodeling is mechanistically active in PTSD-related circuits.

On the protective side, social support and evidence-based psychotherapy following trauma are associated with favorable neuroplastic adaptation and resilience. Emerging interventions — particularly psychedelic substances — are flagged as a promising frontier. The review concludes that neuroplasticity is both a mechanism of PTSD pathology and a therapeutic target, though significant gaps remain in understanding individual variability, translational validity, and optimal intervention timing.